OpenURL Connection Search

Select item for more details and to access through your institution.

COVID‐19 pandemic‐associated chilblains: more links for SARS‐CoV‐2 and less evidence for high interferon type I systemic response.
Published in:
British Journal of Dermatology, 2022, v. 187, n. 6, p. 1032, doi. 10.1111/bjd.21820
By:
- Bessis, Didier;
- Trouillet‐Assant, Sophie;
- Secco, Léo‐Paul;
- Bardin, Nathalie;
- Blanc, Brigitte;
- Blatière, Véronique;
- Chable‐Bessia, Christine;
- Delfour, Christophe;
- Girard, Céline;
- Richard, Jean‐Christophe;
- Gros, Nathalie;
- Le Moing, Vincent;
- Molinari, Nicolas;
- Pallure, Valérie;
- Pisoni, Amandine;
- Raison‐Peyron, Nadia;
- Reynaud, Elisa;
- Schwob, Émilie;
- Pescarmona, Rémi;
- Samaran, Quentin
Publication type:
Article
Cinacalcet as First-line Treatment for Calciphylaxis.
Published in:
2008
By:
- Pallure, Valérie;
- Comte, Christelle;
- Leray-Mouragues, Hélène;
- Dereurel, Olivier
Publication type:
Letter
Impact of the COVID-19 Pandemic on Chronic Inflammatory Dermatoses: Mixed Messages Regarding the Dermatologist's Point of View and the Patient's Concerns.
Published in:
Acta Dermato-Venereologica, 2020, v. 100, n. 8, p. 1, doi. 10.2340/00015555-3610
By:
- FOUGEROUSSE, Anne-Claire;
- MACCARI, François;
- REGUIAI, Ziad;
- BEGON, Edouard;
- PALLURE, Valérie;
- TAIEB, Charles;
- GIRARD, Céline;
- MÉRY-BOSSARD, Laure
Publication type:
Article
Combining Omalizumab with Another Biotherapy.
Published in:
Acta Dermato-Venereologica, 2019, v. 99, n. 4, p. 448, doi. 10.2340/00015555-3140
By:
- FOUGEROUSSE, Anne-Claire;
- BECHEREL, Pierre-André;
- PALLURE, Valérie;
- BOYÉ, Thierry;
- REGUIAI, Ziad;
- GABISON, Germaine;
- BARTHELEMY, Hughes;
- BADAOUI, Antoine;
- MAHÉ, Emmanuel;
- BULAI LIVIDEANU, Cristina
Publication type:
Article

Found: 4

COVID‐19 pandemic‐associated chilblains: more links for SARS‐CoV‐2 and less evidence for high interferon type I systemic response.

Cinacalcet as First-line Treatment for Calciphylaxis.

Impact of the COVID-19 Pandemic on Chronic Inflammatory Dermatoses: Mixed Messages Regarding the Dermatologist's Point of View and the Patient's Concerns.

Combining Omalizumab with Another Biotherapy.